DB-1303 Advanced Solid Tumor Study
Study overview
This multicenter, open-label, non-randomized Phase 1/2a study is evaluating DB-1303 in people with advanced or metastatic solid tumors. Listed open groups include an endometrial cancer cohort and breast cancer cohorts. A first-in-human study introduces an investigational treatment to people under a carefully defined protocol. The study team confirms tumor type, disease status, previous treatment, pathology, and other eligibility requirements.
What the research examines
Early portions commonly focus on safety, tolerability, dose selection, pharmacokinetics, and pharmacodynamics. These measures help researchers understand side effects, how the investigational medicine moves through the body, and its biological effects. Expansion portions may also evaluate preliminary antitumor activity in defined groups. Procedures may include examinations, laboratory tests, imaging, tumor measurements, and scheduled monitoring. DB-1303 is investigational, so its benefits and risks are not fully established.
Asking about participation
Eligibility may depend on cancer type, disease history, prior therapy, general health, laboratory findings, and protocol-specific biomarkers or tissue requirements. Availability can change as cohorts open, pause, fill, or close. Screening does not guarantee enrollment, and contacting California Research Institute does not obligate you to participate.
Participation is voluntary. During informed consent, the research team explains required visits, study procedures, foreseeable risks, alternatives, privacy protections, and participant rights. You may discuss the study with your physician, family, or another trusted adviser before deciding.
For current information, call (323) 660-6200 or email trials@caresinst.org. Please do not email medical records, insurance details, or sensitive health information. This page is educational and does not replace medical advice.